Closely-held PharmaJet will present results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods at the World Vaccine Congress 2023 on April 5.
The presentation will be the first such in-depth comparison and public discussion of existing DNA vaccine administration modalities and their inherent benefits and challenges in the COVID-19 era.
It will discuss the safety, immunogenicity and clinical efficacy of DNA vaccines when administered using needle-free precision delivery systems and alternative methods, including electroporation, gene gun, and needle and syringe delivery.
Topline results of the analysis showed that DNA vaccines delivered needle-free tend to induce immunogenicity that is non-inferior to electroporation. DNA vaccines delivered needle-free also tend to elicit improved immunogenicity, compared with needle and syringe, according to the authors of the publication.
In addition, compared with electroporation and with needle and syringe, needle-free precision delivery systems provide a wider dispersion pattern of the DNA vaccine within tissues and more precise, efficient delivery into cells.
“This comprehensive scientific review clearly shows that needle-free delivery of DNA vaccines can accomplish both outcomes, outperforming alternative methods,” Erin Spiegel, Ph.D., VP clinical and regulatory affairs at PharmaJet, said in a statement.
The data associated with needle-free precision delivery systems “demonstrate this technology platform can be expected to enhance vaccine immune response,” she added.
